11:37 AM EDT, 05/20/2024 (MT Newswires) -- TFF Pharmaceuticals ( TFFP ) said Monday that it is advancing multiple multivalent universal influenza vaccines to protect against seasonal and pandemic viruses into preclinical testing under a collaboration with Cleveland Clinic.

The company said it has selected three hemagglutinin antigen/adjuvant candidate vaccines for testing at Cleveland Clinic Florida. According to TFF, the research collaboration is funded through the National Institute of Allergy and Infectious Diseases.

Shares of TFF Pharmaceuticals ( TFFP ) were down more than 3% in recent trading.

Price: 2.08, Change: -0.07, Percent Change: -3.26